Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response While Receiving Telaprevir, Peginterferon Alfa2a (Pegasys®) and Ribavirin (Copegus®)
Brief Summary: This study is being conducted to learn more about the safety and effect of telaprevir in combination with peginterferon alfa-2a (PEG-IFN) and ribavirin (RBV) in participants with hepatitis C who have never been treated for their hepatitis C virus (HCV). The study is designed to look at the relative benefits of 24 or 48 weeks of total treatment in people who respond quickly to a telaprevir-based treatment.


Options:
A: Arm Label: PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week; Type: PLACEBO_COMPARATOR; Interventions: Biological: Pegylated Interferon Alfa 2a, Drug: Ribavirin, Other: Placebo | Arm Label: Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week; Type: EXPERIMENTAL; Interventions: Biological: Pegylated Interferon Alfa 2a, Drug: Telaprevir, Drug: Ribavirin, Other: Placebo | Arm Label: Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week; Type: EXPERIMENTAL; Interventions: Biological: Pegylated Interferon Alfa 2a, Drug: Telaprevir, Drug: Ribavirin | Intervention Type: BIOLOGICAL; Name: Pegylated Interferon Alfa 2a; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week
B: Arm Label: 1. Placebo + PEG + RBV; Type: PLACEBO_COMPARATOR; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Placebo | Arm Label: 2. Boceprevir + PEG + RBV - 24 Weeks (RGT); Type: EXPERIMENTAL; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Boceprevir | Arm Label: 3. Boceprevir + PEG + RBV - 44 Weeks; Type: EXPERIMENTAL; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Boceprevir | Intervention Type: BIOLOGICAL; Name: Peginterferon alfa-2b (PEG); Assigned to Arm(s): 1. Placebo + PEG + RBV, 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): 1. Placebo + PEG + RBV, 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1. Placebo + PEG + RBV | Intervention Type: DRUG; Name: Boceprevir; Assigned to Arm(s): 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks
C: Arm Label: T12PR24 (eRVR+); Type: EXPERIMENTAL; Interventions: Drug: telaprevir, Drug: ribavirin, Biological: peginterferon alfa-2a | Arm Label: T12PR48 (eRVR+); Type: EXPERIMENTAL; Interventions: Drug: telaprevir, Drug: ribavirin, Biological: peginterferon alfa-2a | Arm Label: T12PR48 (eRVR-); Type: EXPERIMENTAL; Interventions: Drug: telaprevir, Drug: ribavirin, Biological: peginterferon alfa-2a | Arm Label: Other; Type: EXPERIMENTAL; Interventions: Drug: telaprevir, Drug: ribavirin, Biological: peginterferon alfa-2a | Intervention Type: DRUG; Name: telaprevir; Assigned to Arm(s): Other, T12PR24 (eRVR+), T12PR48 (eRVR+), T12PR48 (eRVR-) | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): Other, T12PR24 (eRVR+), T12PR48 (eRVR+), T12PR48 (eRVR-) | Intervention Type: BIOLOGICAL; Name: peginterferon alfa-2a; Assigned to Arm(s): Other, T12PR24 (eRVR+), T12PR48 (eRVR+), T12PR48 (eRVR-)
D: Arm Label: Placebo+PEG2b+RBV, x 44 weeks; Type: PLACEBO_COMPARATOR; Interventions: Biological: Pegylated interferon alfa-2b (SCH 54031), Drug: Ribavirin (SCH 18908), Drug: Boceprevir placebo | Arm Label: Boceprevir+PEG2b+RBV, Response Guided Therapy; Type: EXPERIMENTAL; Interventions: Drug: Boceprevir (SCH 503034), Biological: Pegylated interferon alfa-2b (SCH 54031), Drug: Ribavirin (SCH 18908), Drug: Boceprevir placebo | Arm Label: Boceprevir+PEG2b+RBV, x 44 weeks; Type: EXPERIMENTAL; Interventions: Drug: Boceprevir (SCH 503034), Biological: Pegylated interferon alfa-2b (SCH 54031), Drug: Ribavirin (SCH 18908) | Intervention Type: DRUG; Name: Boceprevir (SCH 503034); Assigned to Arm(s): Boceprevir+PEG2b+RBV, Response Guided Therapy, Boceprevir+PEG2b+RBV, x 44 weeks | Intervention Type: BIOLOGICAL; Name: Pegylated interferon alfa-2b (SCH 54031); Assigned to Arm(s): Boceprevir+PEG2b+RBV, Response Guided Therapy, Boceprevir+PEG2b+RBV, x 44 weeks, Placebo+PEG2b+RBV, x 44 weeks | Intervention Type: DRUG; Name: Ribavirin (SCH 18908); Assigned to Arm(s): Boceprevir+PEG2b+RBV, Response Guided Therapy, Boceprevir+PEG2b+RBV, x 44 weeks, Placebo+PEG2b+RBV, x 44 weeks | Intervention Type: DRUG; Name: Boceprevir placebo; Assigned to Arm(s): Boceprevir+PEG2b+RBV, Response Guided Therapy, Placebo+PEG2b+RBV, x 44 weeks

Answer: C